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 Background & Objective:  The clinical outcomes and treatment options for acute 
myeloid leukemia (AML) patients are highly dependent upon molecular markers. In 
this study, Wilms tumor 1 (WT1) (exons 7 and 9) mutations, single-nucleotide 
polymorphism (SNP) rs16754, and WT1 expression levels in 130 random AML 
patients were screened; FMs-like tyrosine kinase-3 internal tandem duplication 
(FLT3-ITD), nucleophosmin (NPM1), and CCAAT/enhancer-binding protein alpha 
(CEBPA) mutations were also evaluated. 
 Materials & Methods:  Overall, 130 AML patients were recruited for this study. 
WT1 mutations were determined by Sanger sequencing, and expression levels were 
determined by real-time polymerase chain reaction (PCR). The Kaplan-Meier method 
was used to calculate overall survival (OS) and disease-free survival (DFS). 
Results:  The frequency of WT1 mutations in the study population was 5.4%, and it did 
not affect OS (P=0.98), DFS (P=0.97), or complete remission (CR) rates in AML 
patients. The major allele of SNP rs16754 in the current study was A. No significant 
differences were found for OS (P=0.52), DFS (P=0.42), or CR rates among all SNP 
rs16754 genotypes. The overexpression of WT1 was observed in 83% of patients at 
diagnosis. No significant difference was found for OS (P=0.84), DFS (P=0.82), or CR 
rates between AML patients with high and low WT1 expression levels. 
Conclusion:  The results of the current study do not support WT1 mutation, SNP 
rs16754, or WT1 overexpression at diagnosis, as they were found to be poor 
prognostic markers in AML patients. 
 Keywords:  Acute myeloid leukemia, Wilms tumor mutations, Wilms tumor 
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Acute myeloid leukemia (AML) is a genetically and 
epigenetically heterogeneous disease with acquired 
mutations (1). Somatic mutations, such as Wilms tumor 1 
(WT1), FMS-like tyrosine kinase-3 internal tandem 
duplication (FLT3-ITD), nucleophosmin (NPM1), and 
CCAAT/enhancer-binding protein alpha (CEBPA), play 
important roles in the pathogenesis of AML. WT1 is 
located at chromosome 11p13, and it has 10 exons, of 
which exons 7-10 make the zinc finger domain of the WT1 
protein with DNA-binding activity (2). WT1 is primarily 
considered as a tumor suppressor gene and responsible for 
childhood Wilms tumors. Several studies have shown the 
oncogenic properties of WT1 in some tumors. 
WT1 with anti-apoptotic activity takes part in the 
expansion of myeloid cells, and its expression is 
inversely related to cell differentiation. The majority of 
patients with AML have high WT1 expression levels. In 
the French-American-British (FAB) AML subgroups, 
the highest and lowest levels of WT1 expression were 
seen in M3 and M5, respectively (3). Some studies have 
shown a prognostic impact of WT1 expression at 
diagnosis, such that the overexpression of WT1 has been 
linked to a failure to achieve complete remission (CR) 
and low overall survival (OS) rate. However, other 
studies have not confirmed these results (4, 5). 
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Somatic mutations in WT1 occur in approximately 
6%-15% of de novo AML. The majority of mutations 
occur in exons 7-9 and result in loss of function and 
expression of a truncated protein lacking the zinc finger 
domain. WT1 mutations are associated with younger age 
and the existence of FLT3-ITD and CEBPA mutations. 
The exact role of WT1 mutations in the pathogenesis of 
AML is rather controversial. Recent studies have shown 
that WT1 plays an important role in epigenetic 
regulation. WT1 (in combination with TET2 and 
IDH1/2) contributes to the demethylation process. 
Hence, WT1 mutations can disrupt the demethylation 
process (6-8). 
Single-nucleotide polymorphism (SNP) rs16754 (A to 
G substitution at nucleotide position 1297) is located in 
exon 7 of the WT1 gene and apparently confers favorable 
clinical outcomes in adult AML patients. However, 
some studies have failed to confirm such an association 
(9). 
Owing to the cited controversy among current reports, 
in the present study, we assessed the frequency of WT1 
mutations, SNP rs16754, WT1 expression levels, and 
their prognostic impact on patients with AML in an 
Iranian population. 
  
Materials and Methods 
A total of 130 de novo AML patients (81 males and 
49 females) with a median age of 42 years (range=15-
79 years), who were referred to the Hematology-
Oncology and Stem Cell Transplantation Research 
Center of Shariati Hospital, were recruited for our 
study. Informed written consent was obtained from all 
patients in line with the ethical guidelines of Iran 
University of Medical Sciences, which approved this 
study. 
Patients were diagnosed based on the existence of 
blast cells ≥ 20% in bone marrow (BM) smears, and they 
were categorized into subgroups according to the FAB 
classification. Immunophenotyping was performed in all 
cases. Patients with AML-M3 were excluded. 
Treatment Regimens 
All patients were initially treated with induction 
chemotherapy (100 mg/m2/d cytarabine every 24 hours 
[days 1, 3, 5, and 7] and 60 mg/m2 daunorubicin for 
three days). In order to achieve CR, patients received 
one or two courses of induction chemotherapy. The 
definition of CR was defined as ≤ 5% blast in BM, 
recovery of neutrophils and platelets (PLTs), and 
absence of extramedullary diseases. In consolidation 
therapy, allogeneic hematopoietic stem cell 
transplantation was considered for eligible patients, 
while the rest were treated with cytarabine (100 
mg/m2/day every 24 hours for five days) and 
daunorubicin (60 mg/m2 for two days). For patients 
who were refractory or relapsed salvage therapy was 
administered. 
DNA and RNA Extraction 
Genomic DNA was extracted by a salting-out 
procedure. Total RNA was isolated using the Trizol 
reagent (Qiazol, Qiagen, USA). All protocols were 
performed according to the manufacturer’s 
instructions. Further, cDNA synthesis from 1 μg of 
RNA was performed in a 20 μL reaction using random 
hexamers and oligo (dT) according to the 
manufacturer’s instructions using a cDNA synthesis kit 
(Takara Bio Inc., Otsu, JAPAN). 
Real-Time Quantitative Polymerase Chain 
Reaction of WT1 
WT1 expression levels were determined by 
quantitative real-time polymerase chain reaction (PCR) 
using the StepOnePlus Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA). A WT1 
mRNA assay kit (Qiagen, USA) was used to detect 
WT1 gene expression. The ABL housekeeping gene 
was used for normalization. WT1 levels were 
expressed as copies of WT1/ABL× 104, and a copy 
number of ≥ 250 was considered as overexpression. 
Mutation Analysis 
WT1 exons 7 and 9 were amplified using specific 
primers. PCR conditions were as follows: one cycle of 
95°C for three minutes; 35 cycles of 94°C for 30 
seconds, 60°C for 20 seconds, and 72°C for 30 
seconds; and a final extension of 72°C for seven 
minutes. The PCR products were analyzed by 
electrophoresis on a 2.0% agarose gel, and the products 
were then directly sequenced. 
Details of the detection of NPM1, FLT3-ITD, and 
CEBPA mutations were described previously (10, 11). 
Statistical Analysis 
The x2 (chi-square) test was used to analyze 
categorical variables. Continuous variables (age, as 
well as white blood cell [WBC] and PLT counts) were 
analyzed using the Mann-Whitney test. The Kaplan-
Meier method was used to calculate OS and disease-
free survival (DFS). OS was defined as the time from 
the date of initial diagnosis until death from any cause. 
DFS was defined as the duration between the date of 
CR until the date of relapse or death. The log-rank test 
was used to compare the differences in OS and DFS 
between different groups. 
 Results  
 Frequency and Types of WT1 Patients 
Overall, seven mutations were identified in seven of 
130 patients (5.4%). All mutations were located in 
exon 7, and no mutations were found in exon 9. All 
mutations were of the insertion type and ranged from 1 
to 7 bp (Table 1). All WT1 insertion mutations resulted 
in frameshift mutations; these mutations caused a 
truncated protein, which altered its ability to bind to 
DNA. Laboratory data, other molecular aberrations, 
Shahrbano Rostami et al. 111 
      Volume 29, March & April 2021       Journal of Advances in Medical and Biomedical Research 
and clinical characteristics of patients with mutated and 
unmutated WT1 genes are summarized in Table 2. 
No significant differences were found in terms of 
gender, age, WBC, hemoglobin (Hb), PLT counts, or 
FAB classification between patients with and without 
WT1 mutations. Among other molecular aberrations, 
no correlation was found between WT1 mutations, 
NPM1 mutations (P=0.360), or CEBPA mutations 
(P=0.170). However, a correlation was found with 
FLT3-ITD (P=0.010).  
 
Table 1. Characteristics of AML patients with mutated WT1 





1 46/F M4 1328-1334dup S315Vfsx4 FLT3-ITD Relapse/Death 
2 23/F M1 1333-334insCGGT A314Gfsx4 FLT3-ITD/NPM1mut Live 
3 17/M M1 1327-1331dup S313Yfs None Relapse/Death 
4 27/M M2 1325-1326insGACTCTT V311Ffsx6 
FLT3-
ITD/CEBPAmut Relapse/Death 
5 40/M M5 1330-1331insG S313Vfsx4 FLT3-ITD Relapse/Death 
6 52/M M1 1334dup A314Gfsx2 FLT3-ITD Live 
7 48 /F M1 1325-326insGACTCTT V311Ffsx6 NPM1mut Relapse/Death 
 
 
The nucleotide numbering is according to the 
GenBank accession number NM_024426 (transcript 
variant D). The numbering of amino acid residues is 
according to SWISS-PROT protein sequence number 
P19544. 
 














































FAB subtypes:     0.237 
M0 2(1.5%) 0 0.093 2(1.8)  
M1 19(14.6%) 4(57.1)  17(15.7)  
M2 47(36.2%) 1(14.3)  39(36.2)  
M4 45(34.6%) 1(14.3)  40(37.05)  
M5 12(9.2%) 1(14.3)  6(5.55)  
M6 4(3.1%) 0  4(3.7)  
M7 1(0.8%) 0  0  
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aberrations:      
NPM1 
mutation 23(17.7%) 2 (28.5) 0.360 21(19.4) 0.007 
FLT3-ITD 32(24.6%) 5(71.4) 0.10 28(25.9) 0.93 
CEBPA 
mutation 13(10%) 1(14.28) 0.170 9(8.3) 0.175 
Abbreviations: AML, acute myeloid leukemia; WT1, Wilms tumor 1; FAB, French-American-British; ITD, internal tandem 
duplication; WBC, white blood cell; PLT, platelet. 
 
Clinical Outcome and Prognostic Impact of WT1 
Mutations 
According to the standard protocol for induction 
therapy, of the 130 patients with AML, 94 (72.3%) 
achieved CR, 23 (17.7%) were resistant, and 13 (10%) 
died. 
In achieving CR, no significant difference was found 
between patients with and without WT1 mutations 
(P=0.664). Among other molecular aberrations, patients 
with and without NPM1 mutations (P=0.45) and patients 
with and without CEBPA mutations (P=0.263) were 
similar in their achievement of CR. However, in relation 
to FLT3-ITD, a statistically significant difference in 
achieving CR was found between patients with and 
without FLT3-ITD status (P=0.012). 
The five-year OS and DFS rates were calculated 
between patients with and without WT1 mutations. No 
significant differences were found in terms of OS 
(P=0.98) or DFS (P=0.97) between the two groups 
(Figure 1). 
Analysis of WT1 SNP rs16754 in AML Patients 
SNP rs16754 in 130 adult AML patients was 
analyzed. Of the 130 patients, 104 (80%) had genotype 
AA, 22 (16.9%) had genotype AG, and four (3.1%) 
patients carried genotype GG. No significant 
difference was found in terms of gender, age, WBC, 
Hb, and PLT counts among the various genotypes of 
SNP rs16754. 
No correlation was found between SNP rs16754 and 
other molecular aberrations. In achieving a first CR 
after induction therapy, no significant difference was 
observed among the various genotypes of SNP rs16754 
(P=0.490). 
In the next step, OS and DFS in AML patients were 
compared between the genotypes of SNP rs16754. No 
statistically significant difference was observed in OS 
(P=0.52) and DFS (P=0.42) (Figure 2). 
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a) b) 
                    
Figure 1. The survival curve of AML patients according to the mutational status of WT1. a) DFS in overall patients. b) OS 
in overall patients 
Abbreviations: WT1, Wilms tumor 1; AML, acute myeloid leukemia; DFS, disease-free survival; OS, overall survival.  
 
a) b) 
            
 
 
Figure 2. The survival curve of AML patients according to the SNP rs16754 genotype status. a) DFS in overall patients. b) 
OS in overall patients  
Abbreviations: WT1, Wilms tumor 1; AML, acute myeloid leukemia; SNP, single-nucleotide polymorphism; DFS, disease-free 
survival; OS, overall survival.  
 
WT1 Expression in AML Patients 
The frequency of WT1 overexpression at the time of 
diagnosis in the current study was 83.1%. The clinical 
characteristics, laboratory data, and analyses of other 
molecular aberrations are summarized in Table 1. No 
significant differences were found between WT1 
expression levels and clinical characteristics, except in 
WBC count (P=0.034). The median expressions of 
WT1 in relation to WT1 mutations, various genotypes 
of SNP rs16754, and other molecular aberrations were 
also assessed. 
The median expressions of WT1 in AML patients 
with and without WT1 mutations were compared; WT1 
overexpression was seen more often in patients with 
wild-type WT1, though this difference was not 
statistically significant (P=0.6). The median WT1 
114   WT1 Genes as Prognostic Markers in AML Patients 
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expression level was higher in the genotype AA of SNP 
rs16754 than in other genotypes, but, again, the 
difference was not statistically significant (P=0.262). 
Regarding molecular aberrations, only NPM1 
mutations (P=0.007) were associated with WT1 
overexpression. No correlation was found between 
WT1 expression levels and initial CR achievement 
after induction therapy (P=0.46). Furthermore, no 
statistically significant difference was found in OS 
(P=0.84) or DFS (P=0.82) regarding WT1 expression 
levels (Figure 3). 
 
a)                                                 b) 
 
Figure 3. The survival curve of AML patients according to the WT1 expression level status.  a) DFS in overall patients. b) 
OS in overall patients 
Abbreviations: WT1, Wilms tumor 1; AML, acute myeloid leukemia; DFS, disease-free survival; OS, overall survival. 
 
Discussion 
Understanding the prognostic impact of molecular 
aberrations on AML is essential to assessing risk 
stratification. WT1 gene mutation and expression are 
among the molecular markers that have been 
extensively considered in recent years. 
In the present study, the incidence of WT1 mutations 
(5.4%) was lower than in some other studies, including 
one previous study that was also conducted on an 
Iranian population (12.5%) (12). Similar to Mittelmann 
et al., all mutations were of the insertion type and 
located in exon 7, and no mutations were found in exon 
9 (13). Congruent with other studies, no significant 
difference was found between WT1 mutations and 
clinical characteristics, such as gender, age, Hb, WBC, 
and PLT counts (8). 
Hou et al. showed that there was no correlation 
between WT1 mutations and NPM1, FLT3-ITD, and 
CEBPA mutations (6). In other research, Toogeh et al. 
failed to find any association between WT1 mutations 
and FLT3-ITD mutations (12). In this study, neither 
NPM1 nor CEBPA mutations were correlated with 
WT1 mutations, whereas a correlation was observed 
between WT1 mutations and FLT3-ITD positive status 
(P=0.010). 
In contrast to our results, Tien et al. revealed that 
patients with co-occurrence of WT1 mutations and 
CEBPA double mutations had a poor prognosis and 
that BM transplantation may be considered as first-line 
therapy in CR1 (14). 
To assess the prognostic impact of WT1 mutations 
on AML patients, patients were followed for five years, 
and the OS and DFS terms were analyzed. Achieving 
CR and clinical outcomes were compared between the 
two groups of patients, and no significant difference 
was found.  
In contrast to our results, a series of studies have 
shown that patients with mutations have lower CR or 
higher relapse rates than patients without WT1 
mutations. Niktoreh et al. declared that WT1 mutations 
combined with FLT3-ITD show reduced 3y-EFS and 
OS when compared with patients with either WT1 or 
FIT3-ITD and patients with neither of these mutations 
(15). Tanwar et al. evaluated WT1 mutations (exons 7 
and 9) in 100 patients with AML; 17 mutations (exon 
Shahrbano Rostami et al. 115 
      Volume 29, March & April 2021       Journal of Advances in Medical and Biomedical Research 
7=10; exon 9=7) were found. They stated that more 
patients were needed to confirm the link between WT1 
mutations and clinical outcomes (16). 
Consistent with the current results, Gaidzik et al. 
could not show any impact of WT1 mutations on the 
outcomes of patients with AML (8). The discrepancies 
between studies may be due to unknown cooperating 
genetic aberrations or different post-remission 
consolidation therapies. 
Several studies have been conducted on the 
prognostic impact of SNP rs16754 on adult AML 
patients, and the results are inconsistent. Damm et al. 
reported that AG/GG genotypes independently 
predicted improved outcomes in adult AML patients 
(17). Ho et al. reviewed 790 pediatric AML patients 
and revealed that SNP rs16754 independently 
predicted improved OS and DFS (18). Sheng Lou et al. 
and Petit et al. also found that the clinical outcomes of 
adult AML patients with genotype GG are better than 
those with two other genotypes (5, 19). No prognostic 
impact of SNP rs16754 on the clinical outcomes of 
AML patients was found in the current study. Some 
previous studies were unable to confirm that SNP 
rs16754 predicts OS and DFS (18, 20).  
The frequency of WT1 overexpression in the current 
study population was 83.1%, which is in agreement 
with previous research (21). In some studies, WT1 
overexpression at diagnosis has been described as an 
adverse predictor of clinical outcomes. Lyu et al. 
reported that WT1 overexpression by itself is an 
independent and negative predictor of CR, DFS, and 
OS in cytogenetically normal AML patients (22, 23). 
Du et al. showed that AML patients with high WT1 
levels had a lower overall response rate and two-year 
OS when compared with patients with a low copy 
number of WT1 (24). Dongfeng et al. showed that 
AML patients with high level of WT1 had a lower 
overall response rate and 2-year OS compared with 
patients with low copy number of WT1 (25). Mitrovic 
et al. Showed that increased expression of WT1 gene 
detected in high proportion of APL patients could be 
considered as a good indicator for risk stratification to 
improve treatment and outcome of APL patients (26). 
Ebtesam et al. believed that WT1 overexpression is an 
independent negative prognostic marker that could be 
used to evaluate response to induction chemotherapy 
and prognosis of AML patients (27). Shimada et al. did 
not find any correlation between WT1 overexpression 
and poor outcomes in Japanese pediatric AML patients 
(28). The current study failed to show a significant 
difference in CR rate, OS, or DFS in AML patients 
regarding WT1 expression levels. 
 The current results are in line with those of Luo and 
Gaur, who indicated that the median expression of 
WT1 is relatively higher in AML patients without 
mutations when compared to AML patients with 
mutations. However, the difference was not 
statistically significant. The current results also showed 
that patients with NPM1 mutations have higher levels 
of WT1 expression than those without NPM1 
mutations. Differently from the current findings, Luo 
et al. did not find any correlation between WT1 
expression levels and other genetic alterations, such as 
FLT3-ITD, CEBPA, or MLL. Gaur et al. also indicated 
that AML patients with FLT3-ITD or FLT3-TKD 
mutations had a high median copy number of WT1 
transcripts (5, 29). 
 
Conclusion 
The results of the present study indicate that WT1 
mutations, WT1 expression levels, and SNP rs16754 
cannot be considered as prognostic factors in random 
adult patients with AML. Owing to the low sample 
size, low frequency of WT1 mutations, and role of 
unknown cooperating genetic aberrations, the current 
results must be interpreted with caution. It is suggested 
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